This study provides first insights into the involvement of hNOT/ALG3, the human counterpart of the Drosophila Neighbour of TID and yeast ALG3 gene, in various putative molecular networks. HNOT/ALG3 encodes two translated transcripts encoding precursor proteins differing in their N-terminus and showing 33% identity with the yeast asparagine-linked glycosylation 3 (ALG3) protein. Experimental evidence for the functional homology of the proteins of fly and man in the N-glycosylation has still to be provided. In this study, using the yeast two-hybrid technique we identify 17 molecular partners of hNOT-1/ALG3-1. We disclose the building of hNOT/ALG3 homodimers and provide experimental evidence for its in vivo interaction with the functionally linked proteins OSBP, OSBPL9 and LRP1, the SYPL1 protein and the transcription factor CREB3. Regarding the latter, we show that the 55 kDa N-glycosylated hNOT-1/ALG3-1 molecule binds the N-glycosylated CREB3 precursor but does not interact with CREB3's proteolytic products specific to the endoplasmic reticulum and to the nucleus. The interaction between the two partners is a prerequisite for the proteolytic activation of CREB3. In case of the further binding partners, our data suggest that hNOT-1/ALG3-1 interacts with both OSBPs and with their direct targets LRP1 and VAMP/VAP-A. Moreover, our results show that various partners of hNOT-1/ALG3-1 interact with its diverse post translationally processed products destined to distinct cellular compartments. Generally, our data suggest the involvement of hNOT-1/ALG3-1 in various molecular contexts determining essential processes associated with distinct cellular machineries and related to various pathologies, such as cancer, viral infections, neuronal and immunological disorders and CDG. † Present address: Berlin
Introduction
HNOT/ALG3 is the human counterpart of the Neighbour of TID (NOT) gene, which was originally identified in the fruit fly Drosophila melanogaster (Dmel) (1, 2) and its distant relative Drosophila virilis (Dvir) (3). As described previously, sequence comparison of the Dmel and Dvir NOT proteins revealed an identity score of 71% (3) . The identity score between the proteins Dmel NOT56 (2) and hNOT-1/ALG3-1 was estimated at 48% (4) . Both proteins show a 33% identity with the Saccharomyces cerevisiae non-essential asparagine (Asn)-linked glycosylation 3 (ALG3) protein, a dolichol-PP-Man: Man5GlcNAc2-dolichyl-PP mannosyltransferase acting in the asparagine-linked/N-linked glycosylation (5) . Because of the structural homology, a putative association of hNOT/ALG3 with the autosomal recessive multisystemic congenital disorders of glycosylation (CDG), which involves the defective synthesis of N-glycans and under glycosylation of glycoproteins (6, 7) , was concluded. However, unambiguous evidence for both Dmel NOT and its human counterpart as essential components of the N-glycosylation machinery has not been provided yet (4) . The discovery of mutated hNOT/ALG3 transcripts in CDG patients (8) (9) (10) (11) (12) (13) (14) (15) suggested this functional aspect to be of relevance and justifies research on the role of hNOT/ALG3 in the CDG pathology. Our recent study concerning the genomic organization of the gene in question and its transcription in diverse normal and tumorous cells clearly revealed that some of the mutations previously identified in CDG patients are common erratic products of the transcription/splicing machinery and, thus, can be excluded as pathologically relevant (4) . Furthermore, CDG is not the only disease the gene must be considered as relevant to. Recent studies identified hNOT/ ALG3 as a novel cancer biomarker (4, (16) (17) (18) and putative target molecule in mental retardation (MR) not associated with CDG (19) .
In this study, we provide first insights into the complex biology and diversity of the cellular actions of the hNOT/ALG3 gene. Using the yeast two-hybrid (Y2H) technique (20) , we identify the following 17 putative direct interaction partners of hNOT-1/ ALG3-1: synaptophysin-like protein 1 (SYPL1) (21, 22) , lowdensity lipoprotein receptor-related protein 1 (LRP1) (23, 24) , vesicle-associated membrane protein-associated protein A (VAP-A) (25) , sushi-repeat containing protein (SRPX) (26) , FK506 binding protein 8 (FKBP8) (27, 28) , guanylate binding protein 1 (GBP1) (29, 30) , heme oxygenase 2 (HO-2) (31), BCL2/adenovirus E1B19 kDa interacting protein 3 (BNIP3) (32) (33) (34) , oxysterolbinding protein (OSBP) (35) , oxysterol-binding protein-like 9 (36), cluster of differentiation 74 (CD74) (37, 38) , smoothelin (SMTN) (39) , Sec 16 homolog leucine zipper transcription regulator 2 (SEC16 B/LZTR2) (40, 41) , N-Myc downstream regulated 2 protein (NDRG2) (42) , inverted-formin 2 (INF-2) (43, 44) , cytochrome c oxidase subunit 3 (COX3) (45, 46) and c-AMP responsive elementbinding protein 3 (CREB3) (47) . Furthermore, using immunoprecipitation (IP) we provide experimental evidence for the in vivo binding of the protein in question with its partners OSBP, OSBPL9, LRP1, SYPL1 and CREB3, which are associated with the endoplasmic reticulum (ER). Considering the homology of hNOT/ALG3 with the ALG3 dolichol-PP-Man: Man5GlcNAc2-dolichyl-PP mannosyltransferase and the confirmed action of the yeast ALG3 protein as N-glycosyltransferase (5), we analysed the 17 isolated molecules with respect to their N-glycosylation status using diverse bioinformatical tools. These tools were also used to identify protein-protein binding-sites/domains common for both the hNOT/ALG3 proteins and their ligands. Generally, the data described herein are in congruence with recent reports implying hNOT/ALG3 to be a multifunctional player acting in concert with many molecules involved in essential molecular machineries determining cellular processes such as proliferation, differentiation, apoptosis and immune responses. Furthermore, the data suggest its relevance to distinct pathologies, not only CDG.
Results
Molecular partners of hNOT-1/ALG3-1
As described previously, the HNOT/ALG3 gene encodes 17 transcripts, but only the two main forms hNOT-1/ALG3-1 and hNOT-4/ALG3-4 are translated (4) . The remaining 15 forms that are not translated are pathologically not relevant common truncated derivatives resulting from aberrant alternative splicing of the two main forms (4) . The two full-length precursor proteins hNOT-1/ALG3-1, 438 amino acids (aa) long, and hNOT-4/ALG3-4, 390 aa long, share the region corresponding to the aa 67-438 of hNOT-1/ALG3-1 and differ in their N-terminus which determines their distinct subcellular location (4) . The cytosolic hNOT-4/ALG3-4 molecule lacks the N-terminal 67 aa of hNOT-1/ALG3-1, which is equipped with the di-arginine retention/retrieval signal and further functional motifs associated with the location of the latter in the ER (4) .
To get preliminary insights into the molecular contexts, the proteins encoded by hNOT/ALG3 (4) are associated with we performed a search for putative physiological partners of hNOT-1/ ALG3-1 using the Y2H technique (20) . A recombinant expression vector pAS2-1-NOT-1 encoding the full-length hNOT-1/ ALG3-1 molecule (4) was generated and used as a bait to screen the Human Mammary Gland Matchmaker TM cDNA Library (BD Clontech GmbH) which was cloned into the pACT2 vector (cf. Materials and Methods). A total of 6.8Â10 5 clones was screened under highest stringency conditions (cf. Material and Methods). At least 17 clones verified as positive using the b-Gal filter assay ( Fig. 1A and B) were sequenced. In Table 1 , we present the proteins they encode, their subcellular location and the main functions known to date. Interestingly, many of the identified putative physiological partners of hNOT-1/ALG3-1-LRP1 (23, 24) , VAPA/VAMP (25) , FKBP8 (27, 28) , HO-2 (31), BNIP3 (32) (33) (34) , OSBP (35) , OSBPL9 (36) , CD74 (37, 38) , SEC16 B (40, 41) , INF-2 (43, 44) and CREB3 (47)-are located in the ER (Table 1) . Furthermore, the proteins SYPL and VAMP/VAPA (49, 50) , VAMP and OSBP (51), OSBPL9 (52) and FKBP8 (54) are known to be functionally linked (cf. Table 1) .
N-glycosylation status of the molecular partners of hNOT/ALG3
Considering the homology of the hNOT/ALG3 proteins with the ALG3 mannosyltransferase (4) which is known to act in the Nlinked glycosylation (5), we analysed the glycosylation status of the 17 potential binding partners isolated (Table 1) using diverse bioinformatical tools (cf. Material and Methods). As shown in Table 2 , with the exception of HO-2 and COX3 the remaining 15 binding partner candidates of hNOT-1/ALG3-1 (cf. Table 1 ) are equipped with putative sites for the N-glycosylation. However, the experimentally confirmed N-glycosylation and its biological role were described only for CD74 (94) , LRP1 (95) , CREB3 (47, 96) and SRPX (26) . In the case of CD74, LRP1 and CREB3, the N-glycosylation step is essential for the biological activation of the proteins. In the case of SRPX, no sites are present in the normal allele. In contrary, two mutations resulting in a gain of N-glycosylated forms, which are causal in rolandic seizure disorders, are described (61) . These data and our previously described findings (4) support the hypothesis that the action of hNOT/ ALG3 postulated on the basis of its ALG3 homology is not the only one.
Bioinformatical analysis of the hNOT/ALG3 proteins and their ligands with regard to structural similarities relevant in the context of protein-protein binding
Previously we described that the structural elements/sites of the full-length hNOT/ALG3 proteins associated with targeting to the ER, the signal-mediated sorting between the ER and the Golgi apparatus, the N-glycosylation and the post translational processing by sequential cleavage result in derivatives destined to distinct subcellular compartments (4).
To get a preliminary idea of the molecular aspects of the interactions identified (Table 1 , cf. Fig. 1 ), we extended the bioinformatical analysis described previously (4) with respect to structural elements relevant in the context of the biological functionality and protein-protein interactions. As shown in Table 3 , both hNOT/ALG3 proteins are equipped with phosphorylation sites for diverse kinases, including protein kinase B (PKB) (97) , protein kinase A (PKA) (98) , glycogen synthase kinase 3 (GSK3) (99), PI3 kinase-related kinase (PIKK) (100), casein kinase I (CKI) (101), NIMA related kinase 2 (NEK2) (102) , polo-like kinase (Plk) (103) and mitogen activated protein kinase (MAPK) (104) . Furthermore, both are equipped with cyclin recognition The assay was applied to the co-transformants described in (A) grown on both a medium-and high stringency-medium (SD/-Leu/-Trp/-His/-Ade), both containing glucose and X-a-Gal. The clones 1-17 (blue) represent the sequenced putative hNOT-1/ALG3-1 binding partners (cf. Results and Table 1 ). The clones 18 and 19 are negative. Cells co-transformed with the bait and the pACT2-p53 vector (20) and cells co-transformed with the empty vectors pAS2-1 and pACT2 (21) served as negative controls. Cells transformed with the pC11 vector encoding GAL4 and cells co-transformed with the recombinant vectors pAS2-1-Ptc1 1143-1286 and pACT2-Tid 206-318 (146, 125) served as positive controls (22, 23 tor equipped with the GAL4-BD domain and the pACT2-hNOT-1 1-438 vector equipped with the GAL4-AD domain. The expression of the recombinant proteins NOT-1-BD and NOT-1-AD was determined using domain specific antibodies (cf. Material and Methods). As negative controls lysates from Y187 cells transformed with the two empty vectors (C, -1) and with the recombinant pAS2-1-hNOT-1 1-438 and the pure pACT2 (C, -2) vector were used. As positive control lysates from yeast cells transformed with the pCL1 vector encoding the GAL4 factor (C, þ) were used. Tables 1 and 3 ). The BRCT motif (117, cf. Table 3 ) is present in all ligands of hNOT/ALG3 with the exception of the proteins VAPA, FKBP8, CD74 and CREB3. The PTB domain binding motif (113, cf. Table 3 ) is also present in INF2 ( Table 1 ). The Longer mode 2 interacting motif for 14-3-3 proteins (118, cf. Table 3 ) is also present in the hNOT-1/ALG3-1 ligands LRP1, GBP1, OSBP, OSBPL9, SMTN, SEC16B, INF2 and Isoform analysed using the ELM database for functional motifs/domains common with NOT/ALG3 (cf. Tables 2 and 3 ).
CREB3 ( Table 1 ). The proline-rich motif (114, cf. Table 3 ) is also present in the hNOT/ALG3 ligand BNIP3.
Identification of cell lines suitable for confirmation of hNOT-1/ALG3-1 in vivo binding with selected ER associated ligands
We described the expression profiles of the distinct transcripts and the proteins encoded by hNOT/ALG3 in diverse nontumorous and tumorous human cells previously (4) . To confirm the binding of hNOT-1/ALG3-1 (4) with its ER-associated ligands OSBP (35) , OSBPL9 (36), LRP1 (23, 24) , SYPL (21, 22) and CREB3 (47) (cf. Table 1 ) in vivo via IP we first quantified their expression in the same cells (Table 4 ). The quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis was performed according to previously described protocols (4,125) using ligand specific primers (Supplementary Material, Table S1 ). As shown in Table 4 , the genes encoding the ligands of interest are transcribed in all cells previously identified as expressing HNOT-1/ ALG3-1 (4). Thus, in the next step we determined the expression of the ligands relevant for this study in these cells via western blot (see later). This analysis revealed that with the exception of LRP1 all remaining proteins are present in all cells investigated (cf. In vivo confirmation of hNOT/ALG3-1 binding with CREB3 via IP
As shown in Table 1 , we isolated the 371 aa long isoform 2 (I2) of the CREB3 protein (Table 1) , which is known to be a multifunctional player acting in both the cytosol and the nucleus (47,89-93,126,127) as a binding partner of hNOT-1/ALG3-1 (4).
To confirm the interaction of the two molecules in question via IP we first investigated the suitability of the previously described antibodies (abs) a-NOT 1/4 and a-NOT 1 b (4; cf. Materials and Methods) for this analysis. Unfortunately, both abs turned out to be unsuitable for IP. Thus, we generated stable HEK 293 transfectants (T) (Fig. 2 ) by expressing the human proteins NOT-1/ALG3-1 and CREB3 in fusion with the enhanced green fluorescent protein (EGFP) (T-hNOT-1/ALG3-1-EGFP and T-hCREB3-EGFP; cf. Materials and Methods) and used a monoclonal a-GFP ab against this portion of the recombinant proteins (cf. Material and Methods) in order to immunoprecipitate the complexes of interest. As shown in Figure 3A , the a-GFP ab recognizes both recombinant proteins hNOT-1/ALG3-1-EGFP and hCREB3-EGFP (star) and is suitable for IP. The subcellular distribution of the two recombinant proteins corresponds to that described for the native forms ( Fig. 3B and C; cf. NT and T-NOT) (4, 126, 127) . The band of 55 kDa (star) detected in the crude homogenate (CH), the ER fraction (F2) and the IP-a-GFP generated from the ThNOT-1/ALG3-1-EGFP transfectant ( Fig. 3A ; T-NOT) represents the EGFP fused full-length hNOT-1/ALG3-1 precursor molecule (cf. Fig. 3B ; open circle). The band of about 60 kDa detected additionally in the IP-a-GFP ( Fig. 3A ; star) represents the EGFP fused N-glycosylated precursor molecule (cf. Fig. 3B ; NT, closed circle) (4). The size of the detected recombinant hCREB3-EGFP protein, about 95 kDa, suggests that it represents the EGFP fused N-glycosylated CREB3 form (cf. Fig. 3C ; star). As described previously (4), the hNOT-1/ALG3-1 specific a- Fig. 3B ; NT). The latter are specific but not detectable in each preparation and, thus, may represent either further post translationally modified forms (cf. Table 3) or not denatured complexes ( Fig. 3B; þ) . Generally, the hNOT-1/ALG-3-1 pattern detected in the HEK 293 cells shown in Figure 3B corresponds to that described previously for the HT-29 cells (4). In the TphNOT-1/ALG3-1-EGFP transfectant the a-NOT 1 b ab recognizes the native forms and additionally the EGFP fused precursor molecule ( Fig. 3B ; star). Because both the N-glycosylated native form ( Fig. 3B ; NT, closed circle) and the EGFP fused hNOT-1/ ALG3-1 precursor molecule ( Fig. 3B ; T-NOT, star, cf. Fig. 3A ; star) are 55 kDa in size, the corresponding bands on the immunoblots overlap ( Fig. 3B ; closed circle and star). The hNOT-1/ALG3-1 pattern detected in the transfectant confirms our previously published data suggesting the N-glycosylation step to be a prerequisite for the sequential cleavage of hNOT-1/ALG3-1 resulting in at least two cell compartment specific molecules, 37 and 35 kDa in size, destined to the ER and to the nucleus ( Fig. 3B ; open triangle, closed square). In order to immunoprecipitate the native and the EGFP fused CREB3 molecules, polyclonal and monoclonal a-CREB3 abs both against the full-length human CREB3 (cf. Materials and Methods) were applied ( Fig. 3C and D) . As shown in Figure 3 , the polyclonal a-CREB3 ab recognizes in the CH two molecules which are about 44 (open square) and 70 (closed inverted triangle) kDa in size. As mentioned previously, the I2 form isolated as hNOT-1/ALG3-1 ligand consists of 371 aa (cf. Table 1 ). It encodes a protein of a putative molecular weight of 44 kDa (127) . As previously identified by Raggo et al. (127) , the 44 kDa CREB3 molecule corresponds to the cytosolic precursor protein processed to the active nuclear form by regulated intramembrane proteolysis (RIP) (127) . The N-glycosylation of the precursor and its association with the ER is a prerequisite for the processing by RIP (127) , resulting at least in the active transcription factor (TF) which consists of the N-terminal part of the molecule. Whereas the active TF enters the nucleus after the release from the ER (cf. Fig. 3C and D; closed right-pointing triangle) the C-terminus remains in the ER (cf. Fig. 3C and D; open left-pointing triangle).
As shown in Figure 3C and D, we detect both the 44 kDa precursor molecule (open square) and its N-glycosylated 70 kDa form associated with the ER (closed inverted triangle) in the CH of both not transfected cells, the two transfectants and in the appropriate cellular fractions generated from the T-hCREB3-EGFP (T-CREB3) transfectant. Furthermore, in both transfectants we determine the active nuclear CREB3 ( Fig. 3C and D; closed right-pointing triangle) and the C-terminus of the cleaved Nglycosylated CREB3 which remains in the ER ( Fig. 3C and D ; open left-pointing triangle). Thus, the identified CREB3 pattern shown in Figure 3C and D corresponds to that described previously by Raggo et al. (127) . The detection of the cytosolic 44 kDa CREB3 precursor and its ER associated N-glycosylated 70 kDa form in the complex pooled down using the a-GFP ab from the T-hNOT-1/ALG3-1-EGFP transfectant ( Fig. 4D ; T-NOT/IP a-GFP, closed inverted triangle, open square) and the detection of the 55 kDa N-glycosylated hNOT-1/ALG3-1 in the complex pooled down using the a-CREB3 ab from the T-CREB3-EGFP transfectant ( Fig. 3E ; closed circle) confirm the in vivo binding of the two partners in question. Furthermore, the data presented in Figure 3C -E show clearly that the 55 kDa N-glycosylated hNOT-1/ALG3-1 molecule (cf. Fig. 3B ; closed circle) binds the N-glycosylated CREB3 precursor molecule. It does not interact with the proteolytic products specific to the ER and the nucleus ( Fig. 3C and D; closed right-pointing triangle, open left-pointing triangle). As shown in Figure 3C , the a-CREB3 ab recognizes in the cytosol Bold highlight of rel.c. values recognise the differences in the expression levels of the distinct targets in the diverse cells. and the ER also a high molecular species of about 130 kDa (-), as similiarly detected with the hNOT-1/ALG3-1 specific ab ( Fig. 3B; þ) . This band may represent the not denatured complex of the two interacting partners.
In vivo interaction of hNOT-1/ALG3-1 with OSBP and OSBPL9
The two hNOT-1/ALG3-1 interaction partners OSBP and OSBPL9 (cf. Table 1 ) are members of the evolutionarily conserved family of oxysterol-binding proteins (OSBPs) which in mammals are termed oxysterol-binding protein-related (ORP) or OSBP-like (OSBPL) proteins (128) (129) (130) . In this study, we will use the latter name. In humans, this family consists of 12 genes, which encode the proteins OSBP-the founder member -, and OSBPL1-11. On the basis of structural homology, localization in similar cell compartments and common interaction partners the molecules are organized into six subfamilies (128) (129) (130) . The OSBP gene together with OSBP4 builds the subfamily I (128, 131) . The OSBPL9 gene builds the subfamily V (128). All full-length family members are equipped with the conserved C-terminally located sterol-binding domain (SBD), about 400 aa in size, and a pleckstrin-homology domain (PHD) located at their N-terminus (128) (129) (130) (131) . Interestingly, the genes of the subfamilies I, II and V encode the full-length protein forms (L forms) and short (S) forms transcribed from alternative promoters, lacking the PHD and characterized by specific differential expression patterns associated with specific functions (128, 131) . In the case of OSBP, to date only the full-length protein, 807 aa long, with a putative molecular weight of 89 kDa is known (130) . The polyclonal rabbit a-OSBP ab directed against the C-terminal 300 aa of the protein (cf. Materials and Methods) recognizes in the CH of both cells MCF7 and SKBR-3 two main bands, about 100 and 65 kDa in size ( Fig. 4A; closed circle, open leftpointing triangle), and three weaker bands representing molecules with an electrophoretic mobility of about 35, 70 and 130 kDa ( Fig. 4A ; open circle, star, closed right-pointing triangle). The detection of the full-length OSBP ( Fig. 4A ; closed circle) is congruent with the data previously published (131) (132) (133) . The 130 kDa band ( Fig. 4A ; closed right-pointing triangle) may represent a not denatured complex harbouring OSBP or its post translationally modified form(s). As described previously multisite phosphorylation of OSBP is of essential importance for the mediation of its functions (134, 135 ). An about 65 and 35 kDa derivative of OSBP ( Fig. 4A ; open left-pointing triangle, open circle) has not been identified yet. However, because the SBD of OSBP is 74% identical with the corresponding region of the OSBP4 proteins, we consider these bands as putative unprocessed and processed OSBP4S forms identified by Charman et al. (136) .
As shown in Figure 4A , the a-OSBP ab immunoprecipitates the full-length precursor molecule (closed circle), and the 130 and 65 kDa molecules (closed right-pointing triangle, open leftpointing triangle). Staining of the electrophoretically separated denatured IP a-OSBP with the a-NOT1/4 ab resulted in the identification of the 42 kDa hNOT-1/ALG3-1 protein present in the cytosol, ER and the nucleus (4) as the OSBP interaction partner ( Fig. 4A; closed diamond) . The two further bands detected in the CH ( Fig. 4A; The OSBPL9 gene encodes a putative full-length 723 aa long ORPL9L protein with an electrophoretic mobility corresponding to the molecular weight of 95 kDa and the N-terminally truncated ORPL9S form lacking the PHD, 558 aa long, with a molecular weight of about 70 kDa (36, 52 By using an a-OSBPL9 ab (cf. Material an Methods) directed against a central region of OSBPL9 and encompassing the C-terminal portion of the PSD and the N-terminal portion of the SBP two bands of the size of about 68 and 42 kDa ( Fig. 4B ; double open circles, closed left-pointing triangle) were detected in the CH of all cells (shown exemplary for the SK-BR-3 cells) applied in the qRT-PCR analysis (cf. Table 4 ). The molecule with the electrophoretic mobility of 68 kDa corresponds to the OSBPL9S form originally described by Wyles and Ridgway (52) . Interestingly, in the immunoprecipitate solely the 42 kDa molecule is present ( Fig. 4B; IP-a-OSBPL9) . Staining of the immunoblot of the denatured complex with the a-NOT 1/4 ab (4) revealed its interaction with the 42 kDa hNOT-1/ALG3-1 molecule ( Fig. 4B ; closed diamond) which is present in the cytosol, ER and the nucleus (4), as determined similarly for OSBP (Fig. 4A) . Thus, our data suggest that hNOT-1/ALG3-1 interacts with distinct OSBPs and, furthermore, with their direct targets, such as the VAMP/VAP-A protein (cf. Table 1 ) and the LDL family members (see later; cf. Table 1 ).
Similar to the further members of the family containing the FFAT motif both OSBP and OSBPL9 interact directly with the VAMP/VAP-A protein (128) (129) (130) (131) (132) 137) which was also identified as hNOT-1/ALG3-1 ligand (cf. Table 1 ). The latter molecule is a type II integral ER membrane protein acting in a variety of cellular processes including the regulation of lipid transport and homeostasis, membrane trafficking, neurotransmitter release, stabilization of presynaptic microtubules and unfolded protein response (UPR) (35, 139) . Furthermore, both OSBPs and VAMP/ VAP-A also bind and affect the actin and microtubule cytoskeleton (132, 137, 138) . Unfortunately, the commercially available abs against VAMP/VAP-A (cf. Material and Methods) turned out to be unsuitable for IP and, thus, we could not confirm in vivo its interaction with hNOT-1/ALG3-1 and/or its putative presence in hNOT-1/ALG3-1 complexes with the OSBP/OSBPL9 molecules.
In vivo interaction of hNOT-1/ALG3-1 with LRP1
The LRP family encompasses seven structurally related members (139) . The active LRP1, also known as CD91 or a2mac-roglobulin receptor (a2MR), is derived by proteolysis from a N-glycosylated 600 kDa precursor consisting of an 85 kDa carboxy-terminal b-subunit building the transmembrane and intracellular domain and of a non-covalently attached N-terminal a-subunit building the extracellular domain (1). LRP1 not only regulates the cholesterol and lipid metabolism but it also acts as an essential signal transducer and therefore is involved in distinct physiological processes and related pathologies (139) . The clone isolated in the Y2H screen encompasses the cytoplasmic domain (Table 1) . Thus, to immunoprecipitate the LRP1-hNOT-1/ALG3-1 complex (Fig. 4C ) a a-LRP1 ab directed against the 85 kDa b-subunit was used (cf. Material and Methods). As shown in Figure 4C , the ab recognizes and immunoprecipitates two molecules with an electrophoretic mobility corresponding to 85 and 100 kDa ( Fig. 4C; open diamond, þ) . Whereas the 85 kDa band corresponds to the ß-subunit, the 100 kDa molecule may represent a not-denatured complex or a post translationally modified form. In this context, the already described phosphorylation-dependent binding of LRP1 with distinct cytoplasmic adaptor proteins (140) has to be considered in the scope of research on the functional impact of the interaction in question. According to the UniProt database (cf. Material and Methods), the b-subunit is equipped with six phosphorylation sites. Interestingly, as shown above for OSBP and OSBPL9, LRP1 also interacts with the 42 kDa hNOT-1/ALG3-1 molecule ( Fig. 4B ; closed diamond) present in the cytosol, ER and nucleus (4).
In vivo interaction of hNOT-1/ALG3-1 with SYPL1
Two differentially expressed isoforms of the vesicle protein SYPL1 (259 and 241 aa in size) with an electrophoretic mobility corresponding to 32 and 30 kDa are known (21, 22, 142) . The clone isolated in the Y2H screen corresponds to aa 173-259 of I1 and Fig. 4D; closed triangle, closed inverted triangle) correspond to the two forms identified by Windoffer et al. (141) . The molecules migrating at higher molecular weight than predicted ( Fig. 4D; double closed circles, open right-pointing triangle, double open inverted triangles, closed square) may represent post translationally modified SYPL1 molecules. Interestingly, in the IP performed using the a-SYPL1 ab (IP a-SYPL1) only a band of about 90 kDa ( Fig. 4D ; open right-pointing triangle) is detectable. In order to get some explanation for the high molecular weight of the detected molecule we analysed the SYPL1 sequence using the ELM database (http://elm.eu.org/) for sites relevant in the context of post-translational modifications. In addition to the N-glycosylation site (Table 2) , this analysis revealed phosphorylation sites for distinct kinases (CK1, GSK3, PIKK, PKA, PlK and MAPK) similar as determined for the hNOT-1/ALG3-1 molecules (Table 3) and two binding sites for the glycosaminoglycan attachment (143) . Staining of the IP a-SYPL1 with the a-NOT 1/4 ab (4) revealed that the 37 and 20 kDa hNOT-1/ALG3-1 cleavage products of hNOT-1/ALG3-1, which were previously determined in the cytosol and ER (4), interact with SYPL1 ( Fig. 4D ; open triangle, double open diamonds). Staining of the IP performed using the a-GFP ab (cf. Material and Methods) from the T-NOT transfectant with the a-SYPL1 ab revealed the two main forms of SYPL1 ( Fig. 4D ; closed inverted triangle, closed triangle) as interacting partners of hNOT-1/ALG3-1. Taken together, these results suggest that the interaction between the two molecules in question is associated with the proteolytic processing of hNOT-1/ALG3-1 (4).
Discussion
HNOT/ALG3 is the human homolog of the NOT gene originally identified in Dmel (1,2) and its distant relative Dvir (3) as a gene harbouring in its intron the tumour suppressor tumorous imaginal discs (tid) (1-3). As described previously (4), the ALG3 component in its name points to the 33% identity of the putative flies NOT56 protein (1-3) and its human counterpart with the yeast non-essential ALG3 protein, a dolichyl-PP-Man: Man5GlcNAc2-dolichyl-PP mannosyltransferase, which acts in asparagine (Asn)-linked/N-linked glycosylation (5) . Because defects in the synthesis of N-glycans and under glycosylation of glycoproteins are a diagnostic feature in CDG pathology (6), the latter drew the researcher's attention towards the identification of hNOT/ALG3 mutations in CDG patients (7) (8) (9) (10) (11) (12) (13) (14) (15) . To date, from over 1000 described CDG cases in 12 patients 10 mutational events in hNOT/ ALG3 were described (7) (8) (9) (10) (11) (12) (13) (14) (15) . However, in no described case a direct link between the detected mutation in hNOT/ALG3 with failure of its role as mannosyltransferase and, in turn, the causality of the failure of N-glycosylation and the phenotype in CDG patients can be postulated. As we described previously, the gene encodes 17 transcripts of which only two main forms, hNOT-1/ALG3-1 and hNOT-4/ALG3-4, are translated (4). Furthermore, the 15 remaining non-translated transcripts, among them one found in CDG patients (7), represent common aberrant products of the transcription machinery and have to be excluded as pathologically relevant (4). Recent reports suggesting hNOT/ALG3 as a novel target in cancer (4, (16) (17) (18) and CDG independent MR (19) also do not provide hints concerning the mechanisms and cellular processes the gene may be involved in. Thus, to address the cellular and molecular aspects of hNOT-1/ALG3-1's actions and to get primary hints concerning the molecular networks it is involved in we performed a search for molecules directly interacting with the hNOT-1/ALG3-1 protein. As shown in this study, the identified putative molecular partners of hNOT-1/ALG3 represent diverse functional protein classes. This indicates clearly that the molecule in question is a multifunctional player involved in diverse cellular processes, which are associated in violated state with distinct pathologies. Most of the identified hNOT-1/ALG3-1 partners-LRP1, VAMP, FKBP8, HO-2, BNIP3, OSBP, OSBPL9, CD74, SEC16 B, INF-2 and CREB3 (cf. Table 1 )-have already been confirmed as residing within the ER and the Golgi apparatus, similar to and as previously described for hNOT-1/ALG3-1 (4). Furthermore, many of the ligands acting in processes such as the regulation of intracellular protein trafficking, vesicle biogenesis and transport, endocytosis and secretion are functionally linked. The proteins VAMP and SYPL are direct binding partners (144) involved in the regulation of the trafficking of the insulin responsive GLUT4 glucose transporter from intracellular vesicles to the plasma membrane (21, 50) . VAMP and OSBP mediate in concert the export of proteins from the ER (51), the activation of ceramide transport (35) and the regulation of the OSBPL9 partitioning between the ER and Golgi (53) . Both VAMP and FKBP8 regulate the subcellular location of protrudin and determine the neurite formation (145) . Four of the molecules destined to ER-CREB3 (47, 96) , LRP1 (95), CD74 (94) and SRPX (26)-have been experimentally confirmed as N-glycosylated. In the case of LRP1 and CREB3, the essential necessity of the N-glycosylation step for the biological activation of the proteins has been experimentally confirmed (94, 95) . Thus, the question arises whether these interactions may be associated with the putative role of hNOT-1/ALG3-1 in the N-glycosylation process as postulated on the basis of its 33% identity with the yeast ALG3 protein (4). As we show in this study, regarding the interaction of CREB3 and hNOT-1/ALG3-1 the results so far allow to rule out the latter to act as a mannosyltransferase. The N-glycosylated hNOT-1/ALG3 molecule interacts with the N-glycosylated CREB3 precursor. It does not interact with both the active TF, which after releasing from the ER enters the nucleus, and with the C-terminal part of the CREB3 precursor, that remains in the ER. Thus, because the Nglycosylation and association with the ER of the CREB3 precursor is essential for its processing to the active TF by RIP (127), the interaction in question seems to be a prerequisite for the processing of CREB3. In case of LRP1, we show that the 85 kDa bsubunit representing the cytoplasmic domain of the molecule binds with the 42 kDa cleavage product of the N-glycosylated hNOT-1/ALG3-1 located in the cytosol, the ER and the nucleus (4). Interestingly, this processed hNOT-1/ALG3-1 form does also interact with OSBP and OSBPL9. In contrast, the two SYPL1 forms interact with the two further cleavage products of the Nglycosylated hNOT-1/ALG3-1, namely the N-terminal 37 kDa and the C-terminal 20 kDa molecules located in the cytosol and the ER (4). Generally, the OSBP family members, which are cytosolic oxygenated derivatives of cholesterol (oxysterols), maintain essential housekeeping actions associated with the ER and other organelle membranes and act as sterol sensors and regulators of homeostatic responses in lipid metabolism and transport (130) . Although both OSBP and OSBPL9 mediate oxysterols actions, their capacity to bind and transport sterols differs depending on the cellular sterol levels and the membrane compartment (131) . By interaction with VAPA via the FFAT domain (cf. Table 3 ) OSBP localizes to the ER and the Golgi apparatus where it stimulates sphingomyelin (SM) biosynthesis (133) . Furthermore, it occurs in the cytoplasm and in the vesicles near the nucleus where it regulates the sterol metabolism and transport from the lysosomes to the nucleus and it is required for the delivery of cargo destined to the exocytosis (134) . In the nucleus, OSBP supresses the transcription of genes which encode enzymes of the sterol and LDL biosynthesis (130) . Concerning the latter finding, the isolation of LRP1, which acts as a regulator of the cholesterol homeostasis by receptor-mediated endocytosis of cholesterol-rich LDL particles (139) , as a partner of hNOT-1/ ALG3-1 has to be pointed out. The two OSBPL9 proteins L and S, which are in various tissues differentially expressed, play distinct functions in sterol sensing and trafficking (52) . OSBPL9L localizes similar to OSBP to the trans-Golgi network (TGN) and the ER via its PH domain and the FFAT motif. Its knockdown via siRNA results in Golgi fragmentation and impaired trafficking of proteins and cholesterol between the ER and Golgi (52) . Overexpression of the dominant negative OSBPL9S variant results in complete cessation of the protein transport and leads to inhibition of cell growth (52) . The LRP1 protein regulates both the cholesterol and lipid metabolism and acts as an essential signal transducer (137) . The SYPL1 molecule mediates vesicletrafficking processes (143) . Regarding these functions of OSBP, OSBPL9, LRP1 and SYPL1 and considering the fact that they interact in vivo with distinct processed forms of hNOT-1/ALG3-1, the hypothesis that these interactions may be associated with either the involvement of hNOT-1/ALG3-1 in the intercompartmental transport machinery or with its processing via this route seems to be plausible. This hypothesis is consistent with the previously described resistance of hNOT-1/ALG3-1 to the endoglycosidase H (Endo H) which suggests its complex N-glycosylation status that is characteristic for molecules undergoing fast processing and transfer to Golgi (4). Furthermore, it is congruent with distinct structural features of hNOT/ALG3, such as the endosome-lysosome-basolateral sorting signals, which mediate sorting of transmembrane proteins to different compartments of the endomembrane system and to the basolateral plasma membrane of polarized epithelial cells and attachment sites for glycosaminoglycan (4) . The latter is the most abundant heteropolysaccharide located primarily on the surface of cells, in the extracellular matrix (EMC) and in secretory vesicles.
As described previously, the C-terminus of both hNOT/ALG3 proteins is equipped with the di-lysine KKXX motif associated with targeting to the ER (4). However, whereas the hNOT-1/ ALG3-1, which is additionally equipped with the di-arginine LRKR/RRL retention/retrieving signal for ER localization is located in the ER the hNOT-4/ALG3-4 precursor remains in the cytosol (4). Furthermore, both proteins are glycosylated and undergo sequential proteolytic cleavage resulting in derivatives destined to distinct cellular compartments (4) . The N-glycosylation step seems to be a prerequisite for the processing process (4) . The fact that the two translated hNOT/ALG3 proteins differ with respect to their N-terminus but share the portion corresponding to aa 70-438 of hNOT-1/ALG3-1 and, thus, share the distinct structural features which determine their binding and cellular functions suggests that at least some of the putative partners identified may interact with both. The distinct subcellular destination of the two hNOT/ALG3 proteins may act as a determinant maintaining the specificity of their binding with distinct partners in a defined cellular compartment. The abovediscussed findings concerning the in vivo binding of OSBP, OSBPL9, LRP1 and SYPL1 with distinct processed hNOT-1/ALG3-1 forms support this hypothesis, which needs to be addressed in future functional analysis.
Regarding the putative interactions of hNOT/ALG3-1 with its ligands in the context of their relevance for specific cellular processes, the fact that the latter share with hNOT-1/ALG3-1 many functional binding motifs/domains is of importance (Benedikt Hacker, Hendrik Messal, Niels van de Roemer and Ursula Kurzik-Dumke. Identification of the binding domains mediating the interaction of the human NOT-1/ALG3-1 protein with its partners OSBP, OSBPL9, SYPL1, LRP1, VAPA and FKBP8, in preparation). In summary, although the biological reason of the interactions of hNOT/ALG3 with most of its partners is not known yet, both the known cellular actions of these molecules and the known pathological consequences of their malfunction suggest that hNOT/ALG3 may be involved in a variety of cellular processes relevant to diverse pathologies.
Materials and Methods
Isolation of proteins interacting with hNOT-1/ALG3-1 using the Y2H technique
In order to isolate the molecular partners of hNOT-1/ALG3-1, to confirm the binding between the isolated ligands and the bait and to proof if hNOT-1/ALG3-1 builds homodimers, the Y2H technique was employed. In order to isolate hNOT-1/ALG3-1 binding partners the Matchmaker TM GAL4 Two-Hybrid System 3 (BD Clontech GmbH, Heidelberg, Germany) was used according to the manufacturer's protocols. To screen the prey, Human Mammary Gland Matchmaker TM cDNA Library (BD Clontech GmbH) cloned into the pACT2 vector, the recombinant expression bait-vector pAS2-1-hNOT-1 1-438 was used. It was generated by cloning the full-length hNOT-1/ALG3-1 cDNA (4) into the pAS2-1 vector equipped with the GAL4-binding domain (BD). In order to examine the building of hNOT-1/ALG3-1 homodimers, this cDNA was also cloned into the pACT2 vector (pACT2-hNOT-1 ) equipped with the GAL4-activating domain (AD). The superscripted numbers in the vector's name indicate the aa residues of the protein encoded. The corresponding cDNA fragment has been derived from the IRAUp969D0822D clone through EcoRI/XhoI restriction (Acc. Nr. BC002839, RZPDGerman Science Centre for Genome Research, Berlin, Germany, http:/www.rzpd.de/) and after Klenov treatment cloned into the pAS2-1 vector via EcoRI and SmaI. The expression of the bait protein was confirmed by immunoblot using the affinity purified a-NOT1/4 ab directed against the aa 320-333 of hNOT-1/ ALG3-1 (4). The prey (10 mg) and bait (20 mg) DNA were cotransformed into the yeast AH109 cells and grown on the medium-stringency dropout medium containing glucose and Xa-Gal and lacking leucine, tryptophan and histidine (SD-Leu/-Trp/-His/þX-a-Gal). Clones identified as positive under these growth conditions were subjected to further selection by cultivation on a high-stringency medium containing glucose and Xa-Gal and lacking leucine, tryptophan, histidine and adenine (SD/-Leu/-Trp/-His/-Ade/þX-a-Gal). A total of 6.8 Â 10 5 clones was screened. The determination of b-Galactosidase using the b-Gal filter assay was applied to identify putative positive clones. In order to verify the results, the cells were cotransformed with the bait and the recombinant pACT2-p53 plasmid provided with the Y2H kit (negative control), the empty plasmids pAS2-1 and pACT2 (negative controls), the pC11
Vector encoding GAL4 (positive control) and with the previously described recombinant vectors pAS2-1-Ptc1 1143-1286 and pACT2- In order to examine whether hNOT-1/ALG3-1 builds homodimers, the yeast Y187 cells were sequentially transformed with the recombinant vectors pAS2-1-hNOT-1 and pACT2-hNOT-1 . The expression of the recombinant BD-and ADtagged proteins was determined via western blot using the tag specific abs a-GAL4-BD and a-GAL4-AD (Sigma-Aldrich, Munich, Germany) in the following concentrations: 1 mg/ml (a-GAL4-BD) and 0.4 mg/ml (a-GAL4-AD). To disclose the building of hNOT-1/ ALG3-1 homodimers the b-Gal filter assay was applied. The Y187 cells transformed with the empty vectors pAS2-1 and pACT2 served as negative controls. Cells transformed with the pCL1 vector encoding GAL4 served as positive controls.
DNA sequencing and sequence analysis
Gel electrophoretically separated DNA fragments generated by RT-PCR using appropriate primers were extracted from the gels using the GenElute TM Gel Extraction Kit (Sigma-Aldrich, Steinheim, Germany) and purified using the GenElute TM PCR Clean-Up Kit (Sigma-Aldrich) according to the manufacturer's instructions. Sequencing was performed using the BigDy V R Terminator v1.1 Cycle Seqeuncing Kit (Applied Biosystems, Weiterstadt, Germany) and the services of the company GENterprice GmbH (Mainz, Germany).
Cell lines and cell culture conditions
The yeast cells AH109 and Y187 were purchased by Clontech (BD Clontech GmbH). Non-transformed cells were grown on a yeast (Y)/peptone (P)/dextrose (D) (YPD) medium according to the manufacturer's protocols. Depending on the assay, the transformed cells were cultured on a medium-or highstringency-medium as described earlier. The human cell lines HT-29, MCF-7, HeLa, J16/RAPO and Jurkat were purchased from the German Resource Centre for Biological Material (DSMZ GmbH, Braunschweig, Germany). The human cell lines MDA-MB-468, SK-BR-3, HEK-293 and HaCaT were purchased from the Cell Lines Service GmbH (CLS, Eppelheim, Germany). The human T98G cell line (CRL-1690) was purchased from the European Collection of Authenticated Cell Cultures (ECACC, via Sigma-Aldrich). The mouse MOCHA cells were purchased from LGC Standards GmbH (Wesel, Germany). The HaCaT, SK-BR-3, MDA-MB-468, MCF-7 and HEK-293 cells were cultivated on a DMEM/F-12 medium (Sigma-Aldrich GmbH, Munich, Germany). The cell lines HT-29, J16/RAPO and Jurkat were grown on a RPMI-1640 medium (Sigma-Aldrich GmbH) and the cell lines T98G and HeLa on a MEM (Eagle) medium (Biochrom GmbH, Berlin, Germany). All media were supplemented with 10% heatdeactivated FCS (Biochrom GmbH), and 100 U/ml penicillin and 100 lg/ml streptomycin (Sigma-Aldrich GmbH). The MEM (Eagle) medium has been additionally supplemented with 1 volume per cent (v/v%) 100 mM sodium pyruvate solution (SigmaAldrich) and 1 v/v% 100Â MEM non-essential amino acid solution (Sigma-Aldrich GmbH). The cells were analysed for Mycoplasma contamination using the Venor V R GeM Mycoplasma Detection Kit (Minerva Biolabs GmbH, Berlin, Germany) according to the manufacturer's instructions and cultivated in a humidified 5% CO 2 atmosphere at 37 C.
Generation of transient and stable transfectants
The recombinant expression constructs phNOT-1/ALG3-1-EGFP-N3 and pCREB3-EGFP-N3 were generated by cloning the corresponding full-length cDNA fragments via the restriction sites NheI and SmaI into the pEGFP-N3 vector (BD Clontech GmbH) equipped with the neomycin-resistance gene. As templates for the amplification of the sequences which encode the two full-length proteins of interest the IRALp962K1013Q plasmid carrying the hNOT-1/ALG3-1 sequence and the IRAUp969E0760D plasmid carrying the CREB3 sequence were used. Both vectors were purchased by the RZPD-German Resource Centre for Genome Research (Berlin, Germany, http:/ www.rzpd.de/). The fragments of interest were amplified using cDNA specific primers equipped with the cloning sites NheI (5 0 ) and SmaI (3 0 ) (Supplementary Material, Table S1 ). The correct-
ness of the open reading frame (ORF) of the generated recombinant vectors was proven by sequencing. The recombinant plasmid DNA was propagated in the Escherichia coli DH5a cells and purified using the EndoFree V R Plasmid Maxi Kit (Qiagen, Hilden, Germany). In order to generate the stable transfectants used in this study, T-NOT-1/ALG3-1 (T-NOT) and T-CREB3, 2 Â 10 4 HEK 293 cells grown on 96-well plates were transfected with 0.2 and 0.3 lg DNA using the Effectene V R Transfection Reagent (Qiagen) according to the manufacturer's manual. The expression of the EGFP-reporter has been monitored for 24 and 48 h after the transfection using the inverted fluorescence microscope Olympus IX70 and the TILLvisION software (Photonics GmbH; http://tillvision.software.informer.com). To control the efficiency of the transfection with the recombinant vector the cells were transfected with the pure pEGFP-N3 vector. In order to generate a stable transfected clonal cell population, the neomycin-resistant transfectants were diluted in such a way that single cells were seeded into the 96-cell plate. Subsequently, the monoclonal cell cultures were submitted to the above-described selection process.
Quantification of the RNA of the identified hNOT-1/ ALG3-1 ligands by qRT-PCR The quantification of the identified hNOT/ALG3 ligands (cf. Results, Table 1 and Fig. 1 ) was performed by qRT-PCR as described previously (4, 147) . To exclude potential secondary structures and dimerization, the specific primer combinations used in this analysis (Supplementary Material, Table S1 ) were analysed prior to the synthesis using the computer program FastPCR Professional version 5.2.118 (fast-pcr.software.informer.com). With the synthesis of the primers, the Sigma-Aldrich Company (Taufkirchen, Germany) was entrusted. The specificity of all amplification products was confirmed by sequencing. The efficiency (E) of the PCR reactions was optimized for each target and examined in all cells investigated. The E values were calculated using the LinReg tool (124) (http://www.hartfaalcen trum.nl/index.php? main¼files&fileName¼LinRegPCR.zip&desc ription¼LinRegPCR:%20analysis%20of%20quantitative%20PCR %20data&sub¼LinRegPCR). The relative expression levels, 2 ÀDCt , of the transcripts investigated in the diverse cell lines presented in this study were normalized to HGPRT (2 ÀDCt ¼ 100%;
DCt(X) ¼ Ct(X) -Ct(R), X ¼ target of interest, R: reference ¼ HGPRT) and are shown as percentage change 2 -DCt Â 100%. The qRT-PCR analysis was performed using the ABI PRISM 7900HT Fast Real time PCR System (Applied Biosystems, Darmstadt, Germany). Data analysis was performed using the sodium dodecyl sulphate (SDS) 2.4 RT-PCR software provided with the system. Statistical evaluation was performed using the Student's t-test. The reported RNA expression levels are mean values (n ¼ 3) 6 standard deviation (SD) calculated according to the formula:
Preparation of crude protein homogenates, subcellular fractions, IP and Western blotting
Crude protein homogenates were made according to the previously described protocols (125) . Subcellular fractions F1 (cytosolic proteins), F2 (membrane proteins), F3 (nuclear proteins) were isolated using the Qproteome V R Cell Compartment Kit (Qiagen) according to the manufacturer's protocols. In order to quantify the total amount of protein, the Bio-Rad Protein Assay (Bio-Rad Laboratories GmbH, Munich, Germany) was used. Aliquots consisting of 40 lg of total protein were separated under denatured conditions on SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gels (10%). For IP pre-cleared protein lysates made from 10 7 cells were used. Preclearing and IP-reactions (IPs) were performed using the Immunoprecipitation Kit (Roche Diagnostics GmbH, Mannheim, Germany) as described previously (125) . The final volume of the IPs was 60 ll. In order to pull down the complexes of interest using IP, 2-3 lg of the appropriate specific ab was used. All operations were performed at 4 C. For the investigation via immunoblot 15 ll of the IP of interest were separated on 10% SDS-PAGE.
Antibodies and antigens
In the Y2H assays the following polyclonal abs produced in rabbits and purchased by Sigma-Aldrich were used: a-GAL4-AD, generated against a peptide corresponding to aa 867-881 of the AD of the yeast GAL4 protein, and a-GAL4-BD, generated against a peptide corresponding to aa 39-52 of the BD of yeast GAL4. The ab concentration used for the detection via colony and western blot was 0.4 mg/ml for the a-GAL4-AD ab and 1 mg/ml for the a-GAL4-BD ab. To detect the native and EGFP fused hNOT-1/ ALG3-1 molecule and its derivatives, the previously described polyclonal rabbit antisera a-NOT-1 b , specific to its N-terminal aa 1-14, and a-NOT-1/4, against aa 320-333, were used (4). Both abs were applied in a dilution 1 mg/ml in phosphate-buffered saline buffer containing 0.2% I-Block (Life Technologies GmbH, Darmstadt, Germany) and 0.1% Tween (Carl Roth GmbH & Co., Karlsruhe, Germany). Further rabbit polyclonal abs used in this study are a-CREB3 (Abnova, Heidelberg, Germany; Cat. No. H00010488-D01P) against the recombinant full-length GSTtagged human CREB3 protein, a-OSBP (Proteintech, Manchester, UK; Cat. No. 11096-1-AP) against the C-terminal 300 aa of the protein, a-OSBPL9 (Antibodies-Online, Aachen, Germany; Cat. No. ABIN1013879) against a central region of the molecule encompassing the C-terminal portion of the PSD and the N-terminal portion of the SBP, a-LRP1 (Abcam, Berlin, Germany; Cat. No. ab92544) against a peptide derived from the 85 b-subunit, a-SYPL1 (Sigma-Aldrich; Cat. No. SAB3500080) against a 16 aa polypeptide derived from the N-terminus of the protein, a-VAPA (Abnova; H00009218-D01) against the full-length human I1 of VAPA and a-Actin against an N-terminally located epitope (Sigma-Aldrich; Cat.No. A5060). Primary mouse monoclonal abs used in this study are a-GFP (Roche Diagnostics, Mannheim, Germany; Cat. No. 11814460001), directed against the 27 kDa EGFP protein, and a-TBP (Abcam, Cambridge, UK) directed against aa 1-100 of the human TATA binding protein (TBP). For immunodetection by western blot the primary antibodies were used in a dilution 2 lg/ml in TBS blocking buffer (0.05 M Tris/ 0.15 M NaCl, pH 7.5) containing 3% BSA (Sigma). Proteins were visualized using appropriate secondary alkaline phosphatase (AP) conjugated a-mouse IgG and a-rabbit IgG produced in goat, horseradish peroxidase (HRP) conjugated a-rabbit IgG produced in goat and a-mouse IgG-HRP produced in rabbit. The antibodies were purchased by Sigma-Aldrich (Deisenhofen, Germany) and used in a 1:5000 dilution.
Genbank references of the relevant gene sequences
The GenBank accession numbers (Acc.Nrs.) of the identified molecular partners of the hNOT/ALG3 proteins (cf. Results and Table 1 ) and the further sequences analysed within the scope of this study are available at the National Center for Biotechnology Information (NCBI, gb-admin@ncbi.nlm.hih.gov). The fulllength cDNA encoding the hNOT-1/ALG3-1 protein used to generate the recombinant vectors pAS2-1-NOT-1 , ACT2-NOT- Computational DNA and protein analysis 
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